1. Association of lipid-lowering drug targets with risk of cutaneous melanoma: a mendelian randomization study.
- Author
-
Miao L, Miao T, Zhang Y, and Hao J
- Subjects
- Humans, Melanoma, Cutaneous Malignant, Antibodies, Monoclonal, Humanized therapeutic use, Polymorphism, Single Nucleotide, Membrane Transport Proteins genetics, Membrane Proteins genetics, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Ezetimibe therapeutic use, Hypolipidemic Agents therapeutic use, Hypolipidemic Agents pharmacology, Melanoma genetics, Melanoma drug therapy, Mendelian Randomization Analysis, Skin Neoplasms genetics, Skin Neoplasms drug therapy, Proprotein Convertase 9 genetics, Hydroxymethylglutaryl CoA Reductases genetics, Genome-Wide Association Study
- Abstract
Background: Melanoma proliferation is partly attributed to dysregulated lipid metabolism. The effectiveness of lipid-lowering drugs in combating cutaneous melanoma (CM) is a subject of ongoing debate in both in vitro and clinical studies., Method: This study aims to evaluate the causal relationship between various lipid-lowering drug targets, namely 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR, targeted by statins), Proprotein convertase subtilisin/kexin type 9 (PCSK9, targeted by alirocumab and evolocumab), and Niemann-Pick C1-like 1 (NPC1L1, targeted by ezetimibe), and the outcomes of cutaneous melanoma. To mimic the effects of lipid-lowering drugs, we utilized two genetic tools: analysis of polymorphisms affecting the expression levels of drug target genes, and genetic variations linked to low-density lipoprotein cholesterol levels and drug target genes. These variations were sourced from genome-wide association studies (GWAS). We applied Summary-data-based Mendelian Randomization (SMR) and Inverse Variance Weighted Mendelian Randomization (IVW-MR) to gauge the effectiveness of these drugs., Results: Our findings, with SMR results showing an odds ratio (OR) of 1.44 (95% CI: 1.08-1.92; P = 0.011) and IVW-MR results indicating an OR of 1.56 (95% CI: 1.10-2.23; P = 0.013), demonstrate a positive correlation between PCSK9 expression and increased risk of CM. However, no such correlations were observed in other analyses., Conclusion: The study concludes that PCSK9 plays a significant role in the development of CM, and its inhibition is linked to a reduced risk of the disease., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF